Drugs / MAGE-3 Peptide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00254397 | Nov 2005 → Oct 2012 | melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAGE-3 Peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00254397 ↗ |
| Modality | Peptide | “melanoma-specific peptide vaccines, gp100 and MAGE-3” NCT00254397 ↗ |